ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vorolanib

Also written as “EYP-1901”, “CM082” and “CM082 plus JS001”.

Its studies are mostly in Macular Degeneration · Macular Edema · Carcinoma, Renal Cell · Diabetic Retinopathy · Neoplasms, led by 3 companies.

Drug pageVorolanib: every studyAll 35 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 23, 201724 company-led studies, 5 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Betta Pharmaceuticalsits history only141 open or runningphase 3since Mar 23, 2017May 22, 2013Jun 2027phase 1 · NCT07809802
EyePoint Pharmaceuticalsits history only84 open or runningphase 3since Oct 30, 2024Feb 6, 2021Oct 2027phase 3 · NCT07449923
Tyrogenex20 open or runningphase 2since Jan 21, 2015Feb 14, 2011none ahead

Also a collaborator on its studies: SynteractHCR.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tyrogenex only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2011First study: phase 1 study in NeoplasmsFirst studyNCT01296581 · 52 enrolled · United States
  2. Jan 21, 2015Phase 2 study in Macular DegenerationNCT02348359 · 157 enrolled · United States
  3. Jun 9, 2016Named vorolanibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, EYP-1901, CM082

TargetBeta

KDR →read by rule
“Vorolanib, a next-generation vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor (TKI), exhibits unique pharmacodynamic properties that warrant investigation in adjuvant paradigms.”study text, by rule · the study

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
RamucirumabruleEli Lillyphase 358
apatinibruleJiangsu HengRui Medicinephase 347
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 2 Tyrogenex leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02348359Macular Degeneration · United States2TerminatedDec 12, 2017157
NCT01296581Neoplasms · United States1CompletedJan 201452

How it is read

Names in the registry

  • “EYP-1901”, 8 entries
  • “CM082”, 5 entries
  • “CM082 plus JS001”, 3 entries
  • “vorolanib”, 2 entries
  • “X-82”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.